Alpha Teknova (NASDAQ:TKNO) Issues Quarterly Earnings Results

Alpha Teknova (NASDAQ:TKNO - Get Free Report) announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.02, Zacks reports. The company had revenue of $9.60 million during the quarter, compared to analyst estimates of $9.41 million. Alpha Teknova had a negative net margin of 87.17% and a negative return on equity of 35.30%. Alpha Teknova updated its FY 2025 guidance to EPS.

Alpha Teknova Price Performance

NASDAQ:TKNO traded down $0.15 during mid-day trading on Thursday, reaching $6.38. The stock had a trading volume of 57,260 shares, compared to its average volume of 383,216. The stock has a 50-day simple moving average of $5.81 and a two-hundred day simple moving average of $7.11. The stock has a market capitalization of $340.69 million, a PE ratio of -8.61 and a beta of 0.50. The company has a debt-to-equity ratio of 0.12, a current ratio of 4.73 and a quick ratio of 3.94. Alpha Teknova has a 12 month low of $1.16 and a 12 month high of $10.37.

Analyst Ratings Changes

Separately, Craig Hallum started coverage on shares of Alpha Teknova in a research note on Monday, February 10th. They issued a "buy" rating and a $12.00 target price for the company.

About Alpha Teknova

Alpha Teknova, Inc produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.